Drug intelligence / Profile preview

TN-CT120 LM

Development stage: Unknown
Lead developer: Tilray
Modality: Small Molecules
Administration: Oral

Overview

TN-CT120 LM is an investigational fixed-dose oral cannabinoid formulation containing **tetrahydrocannabinol 5 mg** and **cannabidiol 100 mg** per capsule. It was evaluated by the University of California San Diego in a phase Ib/II randomized, double-blind, placebo-controlled crossover pilot study for essential tremor. The formulation was supplied by Tilray and was generally tolerated by most participants, but the small trial did not identify a signal of efficacy for reducing tremor amplitude. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/40248111/?fc=20231022105433&ff=20250420123608&v=2.18.0.post9+e462414))

Brand names: Tilray
Other names: Tilray TN-CT120 LM

Targets

CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on TN-CT120 LM.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TN-CT120 LM.

Explore the full profile